异波帕胺对重度充血性心力衰竭患者的急性血流动力学影响。
Acute haemodynamic effects of ibopamine in patients with severe congestive heart failure.
作者信息
Ghirardi P, Brusoni B, Mangiavacchi M, Bianco L, Col J, Metra M, Dei Cas L
出版信息
Br J Clin Pharmacol. 1985 May;19(5):613-8. doi: 10.1111/j.1365-2125.1985.tb02688.x.
Ten patients with congestive heart failure (CHF), in III and IV NYHA Class, were treated orally with a single dose of ibopamine ranging from 1.2-3.3 mg/kg, and were studied using the Swan-Ganz catheter and thermodilution technique. Cardiac index (CI) and stroke volume index (SVI) were increased, and mean pulmonary pressure (PAP), systemic vascular resistances (SVR) were lowered. Ibopamine increased CI (+33%) and SVI (+26%), and decreased PAP (-17%) and SVR (-24%). All changes were statistically significant. The maximum haemodynamic effect occurred 180 min after ibopamine administration. Blood pressure and heart rate were unaffected. Tolerability was good. This study shows that ibopamine when orally administered to human subjects improves cardiac performance and further investigations on its use as a therapeutic agent in the long term treatment of CHF are recommended.
十名纽约心脏协会（NYHA）心功能分级为III级和IV级的充血性心力衰竭（CHF）患者口服单剂量的异波帕胺，剂量范围为1.2 - 3.3毫克/千克，并使用Swan - Ganz导管和热稀释技术进行研究。心脏指数（CI）和每搏量指数（SVI）增加，平均肺动脉压（PAP）和全身血管阻力（SVR）降低。异波帕胺使CI增加（+33%），SVI增加（+26%），PAP降低（-17%），SVR降低（-24%）。所有变化均具有统计学意义。异波帕胺给药后180分钟出现最大血流动力学效应。血压和心率未受影响。耐受性良好。本研究表明，异波帕胺口服给药于人体可改善心脏功能，建议对其作为CHF长期治疗的治疗药物进行进一步研究。
Zotero 插件